CorTechs Labs Presents Findings on the Creation of Machine Learning Models to Aid Early, Accurate Diagnosis of MS at ACTRIMS 2020

CorTechs Labs reports in the study “Performance Evaluation for MS Identification Models”, CorTechs Labs used a recent version of their flagship product, NeuroQuant 3.0, to compute volumetric brain measurements to train an AI algorithm to create machine learning models for different age ranges to classify multiple sclerosis (MS) subjects.

CorTechs Labs evaluated the performance of these models for identifying MS subjects and studied the differences of feature importance selected by the models based on whole and specific age range data. The company will be presenting its findings at the conference around the understanding that studying volumetric changes in the brain can lead to a much deeper understanding of the effects and symptoms of MS as a disease, and that these models may be used as MS classifiers to assist clinicians in decision making.

“We are dedicated to improving patient outcomes and up-leveling the standard of patient care through best in class clinical applications and patient-centric analysis and reporting,” said Chris Airriess, Ph.D., chief executive officer of CorTechs Labs. “Having two very close friends with the disease, I have seen firsthand the impact MS can have on the lives of patients and their families. We work hard every day to provide software solutions to enable early, accurate diagnosis of MS to ultimately help patients get the treatment they need as soon as possible – and to monitor treatment response to ensure the best possible outcomes. The research being presented at ACTRIMS provides hope for furthering these advancements in the diagnosis and classification of MS.”

CorTechs Labs will have the following two poster presentations at ACTRIMS 2020:

  • Friday, February 28, 11:00 a.m.-12:00 p.m. ET: Performance Evaluation for Multiple Sclerosis Identification Models Based on MR Imaging and Machine Learning (Board No. P183). Presented by Weidong Luo, Ph.D., principal scientist.
  • Session: Poster Session 2 Lunch
  • Friday, February 28, 12:00-1:00 p.m. ET: Updated Recommendations for a Standardized MRI Protocol for Multiple Sclerosis (Board No. LB310). Presented by The Consortium of MS Centers in partnership with select experts for their input and co-authorship, including Marilyn Maes, M.S., RT, clinical specialist and Amy Verrinder, vice president of sales.
  • Session: Poster Session 2 Lunch

CorTechs Labs’ cutting-edge brain imaging analysis provides neurologists, radiologists and clinical researchers worldwide with a convenient and cost-effective means to quantify brain structures to help assess a variety of neurodegenerative conditions.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version